Dudediligence.

Avalo Therapeutics, Inc

AVTXNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

52.9M

on 2026-06-30, from 1.03M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

20M40MMar2024JunSepDecMar2025JunSepDecMar2026Jun$17.75

Newest

$750.0M

S-3 of 2026-01-08. 1 prospectus supplement filed under it since. S-3 ↗

$75.0M

TD Securities (USA), agreement of 2025-06-05. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

23.4 quarters

$400.3M on 2026-06-30 ÷ $17.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2026-05-05Public offering incl. 1.40M pre-funded21,130,000$17.75$375.1M424B5 ↗